Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib

Inclusion Criteria:

* The informed consent form must be signed before any study specific tests or procedures are done
* Male or female patients aged 18 years and older at the first screening visit
* Histologically confirmed diagnosis of advanced or metastatic non adipocyte soft tissue sarcoma (STS)
* Suitable for treatment with pazopanib in an in-label prescription
* Patients with a life expectancy of at least 6 months
* Eastern Co-operative Oncology Group (ECOG) performance status 0-2
* Adequate organ function as given in Table 1
* For patients with previous anthracycline therapy a normal heart function needs to be documented with an left ventricular ejection fraction (LVEF) of minimal 50% (echocardiogram)
* Patients must be willing and able to fill in the Quality of live (QoL) questionnaires using a tablet PC
* Ability to understand and follow study-related instructions
* Confirmation of the subject's health insurance coverage prior to the first visit

Exclusion Criteria:

* Pretreatment with pazopanib
* Contraindications according to the local Summary of product characteristics ( SmPC) of Votrient®
* Patients having to following STS specific tumors

  * adipocyte sarcoma including all subtypes,
  * all rhabdomyosarcoma, which are not alveolar or pleomorph
  * Chondrosarcoma
  * Osteosarcoma
  * Ewing-tumors, i.e. primitive neuroectodermal tumors (PNET), gastrointestinal stromal tumor (GIST)
  * Dermatofibrosarcoma protuberans
  * inflammatory myofibroblastic sarcoma
  * Malignant mesothelioma
  * Mixed mesenchymal and epidermal tumors of the uterus Other malignant underlying diseases with the exception of the following:
  * Free of disease for at least 3 years
  * Completely resected, non-melanoma skin cancer
  * Successfully treated carcinoma in situ
  * Patients with metastases of the central nervous system (CNS) at screening, which are asymptomatic AND do not require treatment with steroids or enzyme-inducing anticonvulsant drugs
  * Patients with metastases of the CNS, which are already treated (operation and/or radiotherapy, radiosurgery or gamma-knife)
* Major surgery or trauma within 28 days before the first dose of study medication and / or presence of a non-healing wound, fracture, or ulcer
* Clinical indications of an active bleeding or a bleeding diathesis
* Known endobronchial lesions or lesions that infiltrate the large pulmonary artery
* Hemoptysis of\> 2.5 mL within 8 weeks before the first dose of study drug
* Existing uncontrolled infection
* Heart rate-corrected QT-time according to the Fridericia's-formula (QTcF) 450 ms in males and 460 ms in females
* History of one or more of the following cardiovascular diseases within the last 6 months:

  * Cardiac angioplasty or coronary stent
  * Myocardial infarction
  * Unstable angina pectoris
  * Coronary artery bypass surgery
  * Symptomatic peripheral arterial disease
* Cardiac insufficiency New York Heart Association (NYHA) functional dass III or IV
* Poorly controlled hypertension defined as systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg
* History of cerebrovascular disease, including transient ischemic attacks (TIA), pulmonary embolism or untreated deep vein thrombosis within 6 months prior to study entry. Patients with deep vein thrombosis who have received therapeutic anticoagulation for a minimum of 6 weeks might be included in the study.
* Clinically significant gastrointestinal changes that increase the risk of gastrointestinal bleeding
* Clinically significant gastrointestinal changes that may affect the absorption of the study drugs
* Treatment with any of the following anti-neoplastic therapies:

  * Irradiation or Tumor embolization within 14 days prior to the first dose of study drug
  * Chemotherapy, immunotherapy, biological therapy, study medication or hormonal therapy within 14 days or 5 half lives of substance (whichever is langer) prior to the first dose of study drug
* If the discontinuation of prohibited medication (see Section 6.9) at least 14 days or 5 half-lives of substance (whichever is langer) prior to the first dose of pazopanib is medically not acceptable or refused by the patient
* A history of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar chemical structure
* Addiction or other diseases that preclude the patient from appropriately assessing the nature and scope as well as possible consequences of the clinical trial
* Pregnant or breast-feeding women
* Women of childbearing potential unless women who meet the following criteria:

  * Post-menopausal (12 months natural amenorrhea without any application of a hormonal contraceptive or hormonal substitution therapy))
  * Postoperatively (6 weeks after bilateral ovariectomy with or without hysterectomy)
  * Regular and correct use of a contraceptive method with error rate \<1% per year such as implants, depot injections, oral contraceptives or intrauterine devices during treatment and up 6 months after end of treatment
  * Sexual abstinence
  * Vasectomy of the partner
* Men of sexual activity with women of childbearing potential who are not willing to use an effective barrier method of contraception during and up to 6 months after the end of therapy